<DOC>
	<DOCNO>NCT00383513</DOCNO>
	<brief_summary>Epratuzumab investigational antibody design help treat Systemic Lupus Erythematosus ( SLE ) . The purpose study obtain additional long-term information regard safety efficacy continue maintenance-cycle administration Epratuzumab .</brief_summary>
	<brief_title>Study Epratuzumab Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Due logistical consideration , UCB decide consolidate Phase II Phase III open-label extension trial . Subjects complete study offer option continue receive epratuzumab participation Phase III open-label extension study SL0012 ( NCT01408576 ) .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Must participate SL0003 SL0004 benefit participation study Development toxicity epratuzumab Significant protocol deviation SL0003 SL0004 study Evidence significant infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Antibody</keyword>
	<keyword>B-Cell Immunotherapy</keyword>
</DOC>